JP7761929B2 - 安全性の高い非ラメラ液晶形成性組成物 - Google Patents

安全性の高い非ラメラ液晶形成性組成物

Info

Publication number
JP7761929B2
JP7761929B2 JP2021574083A JP2021574083A JP7761929B2 JP 7761929 B2 JP7761929 B2 JP 7761929B2 JP 2021574083 A JP2021574083 A JP 2021574083A JP 2021574083 A JP2021574083 A JP 2021574083A JP 7761929 B2 JP7761929 B2 JP 7761929B2
Authority
JP
Japan
Prior art keywords
mono
enoyl
liquid crystal
sorbitan
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021574083A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021153635A5 (https=
JPWO2021153635A1 (https=
Inventor
泰彦 田畑
隆英 村上
浩明 藤堂
祥子 板倉
堅次 杉林
一郎 土黒
昌久 田能村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARNEX INCORPORATED
Original Assignee
FARNEX INCORPORATED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARNEX INCORPORATED filed Critical FARNEX INCORPORATED
Publication of JPWO2021153635A1 publication Critical patent/JPWO2021153635A1/ja
Publication of JPWO2021153635A5 publication Critical patent/JPWO2021153635A5/ja
Priority to JP2025171135A priority Critical patent/JP2026001219A/ja
Application granted granted Critical
Publication of JP7761929B2 publication Critical patent/JP7761929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021574083A 2020-01-27 2021-01-27 安全性の高い非ラメラ液晶形成性組成物 Active JP7761929B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171135A JP2026001219A (ja) 2020-01-27 2025-10-09 安全性の高い非ラメラ液晶形成性組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020011237 2020-01-27
JP2020011237 2020-01-27
JP2020211758 2020-12-21
JP2020211758 2020-12-21
PCT/JP2021/002917 WO2021153635A1 (ja) 2020-01-27 2021-01-27 安全性の高い非ラメラ液晶形成性組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171135A Division JP2026001219A (ja) 2020-01-27 2025-10-09 安全性の高い非ラメラ液晶形成性組成物

Publications (3)

Publication Number Publication Date
JPWO2021153635A1 JPWO2021153635A1 (https=) 2021-08-05
JPWO2021153635A5 JPWO2021153635A5 (https=) 2024-02-02
JP7761929B2 true JP7761929B2 (ja) 2025-10-29

Family

ID=77079915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574083A Active JP7761929B2 (ja) 2020-01-27 2021-01-27 安全性の高い非ラメラ液晶形成性組成物
JP2025171135A Pending JP2026001219A (ja) 2020-01-27 2025-10-09 安全性の高い非ラメラ液晶形成性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171135A Pending JP2026001219A (ja) 2020-01-27 2025-10-09 安全性の高い非ラメラ液晶形成性組成物

Country Status (5)

Country Link
US (1) US20230105725A1 (https=)
EP (1) EP4098281A4 (https=)
JP (2) JP7761929B2 (https=)
CN (1) CN115461084B (https=)
WO (1) WO2021153635A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004059470A (ja) 2002-07-26 2004-02-26 Kanebo Ltd 養毛料
WO2011078383A1 (ja) 2009-12-25 2011-06-30 株式会社サイトパスファインダー 低粘度液晶化合物
JP2012502922A (ja) 2008-09-22 2012-02-02 ザ プロクター アンド ギャンブル カンパニー 特定のポリ分枝状アルデヒド、アルコール、界面活性剤及びそれらに基づく消費者製品
WO2014178256A1 (ja) 2013-05-01 2014-11-06 株式会社ファルネックス 癒着防止剤
JP2016504353A (ja) 2012-12-28 2016-02-12 チョン クン ダン ファーマシューティカル コーポレーション ＧｎＲＨ誘導体の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
JP2016508140A (ja) 2012-12-28 2016-03-17 チョン クン ダン ファーマシューティカル コーポレーション カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
JP2019099478A (ja) 2017-11-30 2019-06-24 株式会社ファルネックス 非ラメラ液晶再構成能を有する粉末微粒子製剤
WO2019204869A1 (en) 2018-04-26 2019-10-31 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
US7846903B2 (en) 2004-10-19 2010-12-07 National Institute Of Advanced Industrial Science And Technology Type II cubic liquid crystal composition
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
MX350929B (es) * 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.
WO2014101051A1 (en) * 2012-12-27 2014-07-03 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
KR101601035B1 (ko) * 2013-02-28 2016-03-08 주식회사 종근당 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물
US10814351B2 (en) 2013-08-12 2020-10-27 The Boeing Company High-viscosity sealant application system
JP2019193684A (ja) * 2016-09-05 2019-11-07 株式会社ファルネックス 油分を含むエマルションを用いた癒着防止剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004059470A (ja) 2002-07-26 2004-02-26 Kanebo Ltd 養毛料
JP2012502922A (ja) 2008-09-22 2012-02-02 ザ プロクター アンド ギャンブル カンパニー 特定のポリ分枝状アルデヒド、アルコール、界面活性剤及びそれらに基づく消費者製品
WO2011078383A1 (ja) 2009-12-25 2011-06-30 株式会社サイトパスファインダー 低粘度液晶化合物
JP2016504353A (ja) 2012-12-28 2016-02-12 チョン クン ダン ファーマシューティカル コーポレーション ＧｎＲＨ誘導体の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
JP2016508140A (ja) 2012-12-28 2016-03-17 チョン クン ダン ファーマシューティカル コーポレーション カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
WO2014178256A1 (ja) 2013-05-01 2014-11-06 株式会社ファルネックス 癒着防止剤
JP2019099478A (ja) 2017-11-30 2019-06-24 株式会社ファルネックス 非ラメラ液晶再構成能を有する粉末微粒子製剤
WO2019204869A1 (en) 2018-04-26 2019-10-31 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
白石 盛裕 他，Ｐ－６７＊ 非ラメラ液晶リン脂質混合体からのＦＤ－４放出性に及ぼすリン脂質添加の影響，第３５回日本ＤＤＳ学会学術集会プログラム予稿集，2019年06月15日，第１９２頁

Also Published As

Publication number Publication date
CN115461084A (zh) 2022-12-09
WO2021153635A1 (ja) 2021-08-05
CN115461084B (zh) 2026-03-27
JP2026001219A (ja) 2026-01-06
EP4098281A1 (en) 2022-12-07
US20230105725A1 (en) 2023-04-06
EP4098281A4 (en) 2024-03-20
JPWO2021153635A1 (https=) 2021-08-05

Similar Documents

Publication Publication Date Title
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
CA2409854C (en) Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds
ES2282730T3 (es) Emulsiones de perfluorocarburos con tensioactivos no fluorados.
JP6078660B2 (ja) ＧｎＲＨ誘導体の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
US10322073B2 (en) Apparatus and method for preparing cosmeceutical ingredients containing epi-dermal delivery mechanisms
EP2685962A1 (en) Topical nitric oxide systems and methods of use thereof
EP2992910A1 (en) Adhesion preventing agent
KR20140105436A (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
US11992483B2 (en) Emulsions for local anesthetics
CN115804771B (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
ES2377352T3 (es) Nuevas composiciones a base de taxoides
US20130034538A1 (en) Reverse hexagonal mesophases (hii) and uses thereof
JP7761929B2 (ja) 安全性の高い非ラメラ液晶形成性組成物
KR102745034B1 (ko) 수분 감응성 졸-겔 상전이 기반 유착방지용 조성물
EP4378452A1 (en) Non-lamellar liquid crystal-forming composition and use thereof
ES2269200T3 (es) Formulacion de liposomas de dimaleato de 6,9-bis-((2-aminoetil)-amino)benzo(g)isoquinolin-5,10-diona.
ES2283423T3 (es) Emulsion estructurada de anfotericina b.
JP2000510857A (ja) シクロスポリンと少なくとも一種のアルファ―グリセロリン酸エステルから成るキャリアとを含有する薬剤組成物
RU2448731C2 (ru) Фосфолипидная композиция
JPH05501714A (ja) リポソーム組成物
Sguizzato Nanotechnological strategies for topical administration of active compounds

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251009

R150 Certificate of patent or registration of utility model

Ref document number: 7761929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150